Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 14/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14275063 | 1.00 | CXCR4 (0.50) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 | |
| SCHEMBL14275061 | 0.86 | HDAC1 (0.51) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 | |
| SCHEMBL30486101 | 0.85 | HDAC1 (0.52) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 | |
| SCHEMBL30096620 | 0.85 | HDAC1 (0.55) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 | |
| SCHEMBL29067448 | 0.85 | HDAC1 (0.52) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 | |
| SCHEMBL21784360 | 0.84 | HDAC1 (0.51) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 | |
| SCHEMBL30096642 | 0.84 | CXCR4 (0.53) | CXCR4CYP2D6HDAC1HDAC6OPRM1 | |
| SCHEMBL4203768 | 0.84 | CXCR4 (0.53) | CXCR4CYP2D6HDAC1HDAC6OPRM1 | |
| SCHEMBL5050982 | 0.84 | CXCR4 (0.53) | CXCR4CYP2D6HDAC1HDAC6OPRM1 | |
| SCHEMBL3996453 | 0.83 | HDAC1 (0.56) | CXCR4CYP2D6HDAC1HDAC6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171740-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171740-A1 | Chemical Compounds | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CYP2D6 4282/4885HDAC1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.